Efficacy and safety of canagliflozin 300 mg in overweight and obese type 2 diabetes mellitus patients in a real-world setting: COLOR study

Efficacy and safety of canagliflozin 300 mg in overweight and obese type 2 diabetes mellitus patients in a real-world setting: COLOR study

Background and Aims: To assess the efficacy and safety of canagliflozin (CANA, 300 mg/d) in overweight and obese patients with type 2 diabetes mellitus (T2DM). Methods: In a single centre, retrospective, observational study, we included overweight or obese patients with T2DM who had HbA1c >7% and...

Full description

Bibliographic Details
Main Authors: Pankaj Aneja, Gaurav Bhalla, Neeti Parvesh, Kunal Aneja, Kashish Aneja
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2019-01-01
Series:Indian Journal of Endocrinology and Metabolism
Subjects:
Canagliflozin
HbA1c
India
obese
type 2 diabetes mellitus
Online Access:http://www.ijem.in/article.asp?issn=2230-8210;year=2019;volume=23;issue=3;spage=307;epage=311;aulast=Aneja

Internet

http://www.ijem.in/article.asp?issn=2230-8210;year=2019;volume=23;issue=3;spage=307;epage=311;aulast=Aneja

Similar Items